A biotechnology company announced the successful dosing of its first subject in its Phase 2 clinical trial for COVID-19 DNA vaccine candidate, INO-4800, in China.
The Phase 2 clinical trial being conducted in China will enroll approximately 640 participants who are 18 years or older.
INOVIO and Advaccine Biopharmaceuticals Suzhou Co., Ltd. announced in a press release on December 10, 2020, the dosing regimen involves two vaccinations at 0 and 28 days, with either 1.0 mg or 2.0 mg dosing levels and is similar to the Phase 2 segment of Phase 2/3 clinical trial in the USA.
Pennsylvania Developed COVID-19 Vaccine Candidate Expands Study in China
Ulcerative Colitis Treatment Prepares for Phase 3 Study
A clinical-stage biotechnology company announced the progression of its development program for its lead drug candidate, ABX464, into phase 3 preparation for the treatment of moderate-to-severe ulcerative colitis (UC).
ED Visits for Peds Asthma Plunged Under COVID-19 Lockdown
Rate of emergency department visits decreased 80 and 82 percent in 2020 versus previous two years for week starting March 22
Neurologic Complications of COVID-19 Described
Most common neurologic findings in patients hospitalized for COVID-19 include altered mental status, fatigue, headache, stroke
FDA Authorizes First OTC COVID-19 Home Test Collection Kit
Last week, the agency also authorized an at-home test collection kit for COVID-19 and flu, available by prescription
Kidney Disease Leading Risk Factor for COVID-19 Hospitalization
COVID-19 patients with end-stage renal disease 11 times more likely to be hospitalized versus patients with no kidney disease
Deaths Up During Pandemic for Those With Rare Autoimmune Disorders
Individuals with rare autoimmune rheumatic diseases have prominently increased risk for death versus general population
Risk Factors for Severe COVID-19 Up in Cancer Survivors
Cancer survivors also have increased risk for influenza hospitalization/death compared with cancer-free controls
FDA Advisory Committee OKs Pfizer-BioNTech COVID-19 Vaccine
Committee recommends emergency use authorization of the vaccine; vaccine to be distributed within 24 hours of EUA
American Indians/Alaska Natives Have Elevated COVID-19 Mortality
Disparity between AI/AN and White individuals largest for those aged 20 to 49 years